Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
LifeArc and University of Cape Town partner for drug resistance R&D
by Sarah Braner
November 25, 2024
| A version of this story appeared in
Volume 102, Issue 37
Credit: LifeArc
Team members from LifeArc and the Holistic Drug Discovery and Development Centre
LifeArc and the University of Cape Town’s Holistic Drug Discovery and Development Centre have partnered to create an institute at the center for studying and combating antimicrobial resistance. Research efforts will focus on multidrug resistant gram-negative bacteria; special emphasis will be on the antibiotic carbapenem and colistin-resistant Acinetobacter baumannii. LifeArc has put more than $6 million into the partnership.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X